Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Mogamulizumab Q4week Dosing in Participants With R/R CTCL

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed

  • 0 views
  • 04 Oct, 2022
  • 5 locations
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

The purpose of this study is to determine the efficacy of the combination of LD-TSEBT and mogamulizumab in patients with MF and SS. And to evaluate the secondary measures of clinical benefit of

sezary syndrome
lymphoma
t-cell lymphoma
renal function test
malignant disease
  • 19 views
  • 25 Apr, 2022
  • 1 location
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

This phase Ib/II trial investigates the side effects of mogamulizumab and extracorporeal photopheresis and to see how well they work in treating patients with Sezary syndrome or mycosis

cutaneous lymphoma
sezary syndrome
lymphoma
t-cell lymphoma
cytotoxic chemotherapy
  • 0 views
  • 10 Jul, 2022
  • 1 location
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma

sezary syndrome
lymphoma
measurable disease
mycosis
antibiotics
  • 0 views
  • 07 Oct, 2022
  • 1 location
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T

  • 0 views
  • 14 Oct, 2021
  • 1 location
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

lymphoma
t-cell lymphoma
antineoplastic agents
cancer
neutrophil count
  • 0 views
  • 04 Oct, 2022
  • 1 location